Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Comparison: Peptide Access Models in 2026

| Access Model | Peptides Available | Prescriber Requirements | Patient Eligibility Documentation | Cost Range (Monthly) | Regulatory Oversight | Professional Assessment ||—|—|—|—|—|—|| Telehealth Compounded Semaglutide | Semaglutide only (tirzepatide removed

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • | Access Model | Peptides Available | Prescriber Requirements | Patient Eligibility Documentation | Cost Range (Monthly) | Regulatory Oversight | Professional Assessment ||—|—|—|—|—|—|| Telehealth Compounded Semaglutide | Semaglutide only (tirzepatide removed Feb 2026) | Active medical license in patient's state; synchronous consultation (Model A states) or asynchronous with photo ID (Model B) | Metabolic panel within 90 days; BMI ≥27 with comorbidity or ≥30 | $200–$450 | FDA oversight of 503B facilities; state medical board prescribing standards | Compliant access pathway for weight management under updated 2026 rules. Tirzepatide no longer available through this model || Brand-Name GLP-1 (Ozempic, Wegovy, Mounjaro) | Semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro) | Standard prescribing authority; no telehealth-specific restrictions beyond state telemedicine laws | Insurance prior authorization typically required; same BMI thresholds | $900–$1,400 without insurance | Full FDA a